Title: Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in BXPC-3 and PANC-1 human pancreatic cancer cells
Abstract: Objective To assess the cellular mechanism of schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in BXPC-3 and PANC-1 human pancreatic cancer cells. Methods The EGFR and K-ras gene mutation were examined by qPCR-HRM. The expression and phosphorylation of EGFR,HER3,AKT and c-MET were determined by Western blotting. Results The EGFR gene of PANC-1 and BXPC-3 cells were wide-type and PANC-1 cells harbored a specific mutation in K-ras exon. p-EGFR,p-HER3 and p-AKT in sequential erlotinib pemetrexed group were significantly inhibited compared with other groups( P 0. 05). The results showed that there was no significant change in the phosphorylation level of MET in different schedules groups. Conclusion The enhanced inhibitory effect of erlotinib following pemetrexed may relate with pemetrexed enhances the antitumor activity of erlotinib by activating the EGFR / HER3 / AKT pathway.
Publication Year: 2013
Publication Date: 2013-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot